Innovative AI Advancement Aims at Cystic Fibrosis Protein

Buzzline

Researchers appear to be nearing a significant advancement in the treatment of cystic fibrosis. The Cystic Fibrosis Foundation has collaborated with the biotech firm Antiverse to leverage cutting-edge artificial intelligence to create antibodies that specifically target the CFTR protein — the primary protein impacted in cystic fibrosis.  For many years, identifying antibodies that can engage with membrane proteins like CFTR has proven to be exceedingly challenging. Conventional techniques may require one to two years and frequently do not succeed. Antiverse is confident that its generative AI platform can significantly shorten this timeframe by developing therapeutic antibodies in under four months.  By utilizing AI modeling alongside rapid laboratory testing, the company can swiftly create, evaluate, and refine antibodies aimed at the extracellular domains of intricate proteins. These antibodies undergo initial screening in specialized cell lines, followed by testing in native cell models facilitated by the Cystic Fibrosis Foundation.  In addition to this collaboration, Antiverse has successfully secured $9.3 million in new funding to enhance its pipeline. The company is directing its efforts towards diseases where conventional antibody discovery has faced challenges, such as metabolic disorders, lung ailments, and complex receptor targets.  If this AI-enhanced platform proves effective, it could pave the way for new therapies for conditions that have long eluded scientific treatment.

Transcript

00:00What if AI could solve one of the toughest problems in cystic fibrosis,

00:03and do it in months instead of years?

00:05That is exactly what Antiverse is trying to do.

00:08For decades, scientists have struggled to design antibodies that can target the CFTR protein.

00:14This protein is damaged or missing in people with cystic fibrosis,

00:18and its tiny shifting structure makes it incredibly hard to reach.

00:22But now the Cystic Fibrosis Foundation is betting on a breakthrough.

00:26Antiverse uses powerful generative AI and a lab in the Loop platform.

00:30It designs and tests antibodies in fast cycles,

00:33finding what used to take years in just four months.

00:36The company screens these antibodies in special cell lines.

00:39Then the Foundation tests them in models that mimic the human body.

00:43If it works, this could unlock a whole new class of CF treatments.

00:47Antiverse just raised more funding to push forward,

00:50and its AI engine is already being used to crack other hard-to-reach targets.

00:54From metabolic disorders to lung diseases.

00:57Turn AI into a tool that can finally hit the proteins science could never reach.

01:02And open the door to treatments once thought impossible.

01:05Top 5

01:05Down

Category

Transcript

Comments

Recommended